IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

Rhea-AI Summary

IDEAYA Biosciences (Nasdaq:IDYA) announced a late-breaking oral presentation of Phase 1 expansion results for IDE397, a first-in-class, oral MAT2A inhibitor, in MTAP-deletion urothelial and non-small cell lung cancer (NSCLC) patients. The presentation will take place at the 36th EORTC-NCI-AACR Symposium in Barcelona, Spain, on October 25, 2024.

Dr. Benjamin Herzberg from Columbia University will present the results in a plenary session. Additionally, IDEAYA will present two posters: one on the combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors, and another on IDE161, a potential first-in-class PARG inhibitor targeting solid tumors with replication stress and DNA repair vulnerabilities.

Positive

• Presentation of Phase 1 expansion results for IDE397, a first-in-class MAT2A inhibitor
• IDE397 targets MTAP-deletion urothelial and non-small cell lung cancer
• Late-breaking oral presentation at a major oncology symposium
• Additional poster presentations on MAT2A and PARG programs

Negative

• None.

Insights

Medical Research Analyst

The late-breaking oral presentation of IDE397's Phase 1 expansion results in MTAP-deletion lung and urothelial cancer is a significant development for IDEAYA Biosciences. IDE397, as a first-in-class MAT2A inhibitor, represents a novel approach in precision oncology. The focus on MTAP-deleted tumors indicates a targeted strategy that could potentially address an unmet medical need.

Key points to consider:

• The presentation at a major oncology symposium (EORTC-NCI-AACR) suggests the data is considered important by the scientific community.
• Phase 1 expansion results often provide initial efficacy and safety signals, which are important for determining the potential of a new drug.
• The inclusion of both NSCLC and urothelial cancer patients broadens the potential application of IDE397.
• Additional poster presentations on preclinical data for MAT2A and PARG programs indicate a robust pipeline and ongoing research efforts.

For investors, this news could signal progress in IDEAYA's drug development efforts, potentially impacting the company's valuation if the results are positive. However, it's important to note that Phase 1 data, while promising, is still early-stage and further clinical trials will be necessary to confirm efficacy and safety.

SOUTH SAN FRANCISCO, Calif., Oct. 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a late-breaking oral presentation of the Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor in methylthioadenosine phosphorylase (MTAP)-deletion urothelial and non-small cell lung cancer (NSCLC) patients at the 36th edition of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place on October 23 to 25, 2024, in Barcelona, Spain.  In addition, IDEAYA will also have additional poster presentations at the EORTC-NCI-AACR Symposium highlighting preclinical data for the MAT2A and PARG programs.

Details for the oral presentation are as follows:
Presenter: Dr. Benjamin Herzberg, MD, Assistant Professor, Columbia University
Title: Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)
Abstract #: 501 LBA
Session: Plenary Session 7, Late Breaking Abstracts and Proffered Papers: Novel discoveries in drug development
Date and Time: Friday, October 25, 2024 at 3:00pm CEST

Poster presentation details are below:
Author: Garbett, D. et al.
Title: The mechanistic basis of both deep and durable antitumor activity by combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors
Poster Number: PB204
Session Title: Combination Therapies
Date and Time: Thursday, October 24, 2024, 9:00am - 5:30pm CEST, Exhibition Hall

Author: Munoz, D. et al.
Title: IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets solid tumors with replication stress and DNA repair vulnerabilities
Poster Number: PB337
Session Title: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)
Date and Time: Friday, October 25, 2024, 9:00am - 3:00pm CEST, Exhibition Hall

The oral presentation and posters will be available online at https://ir.ideayabio.com/events following the presentations.

About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.

Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the timing and content of future presentations. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations  
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-late-breaker-oral-presentation-of-ide397-phase-1-expansion-results-in-mtap-deletion-lung-and-urothelial-cancer-at-the-36th-edition-of-the-eortc-nci-aacr-symposium-302267595.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What is IDE397 and what types of cancer does it target?

IDE397 is a first-in-class, oral MAT2A inhibitor targeting MTAP-deletion urothelial cancer and non-small cell lung cancer (NSCLC).

When and where will IDEAYA Biosciences (IDYA) present the Phase 1 expansion results for IDE397?

IDEAYA Biosciences will present the Phase 1 expansion results for IDE397 on October 25, 2024, at the 36th EORTC-NCI-AACR Symposium in Barcelona, Spain.

What other research will IDEAYA Biosciences (IDYA) present at the EORTC-NCI-AACR Symposium in October 2024?

IDEAYA will present two additional posters: one on combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors, and another on IDE161, a potential first-in-class PARG inhibitor for solid tumors with specific vulnerabilities.

Who will present the IDE397 Phase 1 expansion results for IDEAYA Biosciences (IDYA)?

Dr. Benjamin Herzberg, Assistant Professor at Columbia University, will present the IDE397 Phase 1 expansion results.